Most tellingly, lessons from these animal models have supported the development of highly effective therapeutics, expanding our options from the TNF inhibitors that were the only biologic approach approved for ankylosing spondylitis 10 years ago. The gene discussed is TNF; the disease is ankylosing spondylitis.